CEACs for the imminent preterm birth models. The blue line depicts the probability of magnesium sulphate being cost-effective across all willingness-to-pay values up to $100,000. The red line depicts the probability of the alternative (no treatment) being cost effective across all willingness-to-pay values up to $100,000.
Bickford et al. BMC Health Services Research 2013 13:527 doi:10.1186/1472-6963-13-527